Skip to main content
Top
Published in: Medical Oncology 10/2016

01-10-2016 | Short Communication

Association between polymorphisms in xenobiotic detoxification-related genes with prognosis of epithelial ovarian cancer

Authors: Juliana Carron, Angelo Borsarelli Carvalho Brito, Ana Carolina Mourão Torelli, Cristiane Oliveira, Sophie Françoise Mauricette Derchain, Carmen Silvia Passos Lima, Gustavo Jacob Lourenço

Published in: Medical Oncology | Issue 10/2016

Login to get access

Abstract

This study aimed to evaluate whether GSTM1 and GSTT1 (presents or nulls), GSTP1 c.313A>G and NQO2 c.-102A>C polymorphisms, involved in xenobiotic detoxification pathways, alter outcomes of epithelial ovarian cancer (EOC) patients. DNA from 84 EOC patients diagnosed at the University of Campinas Academic Hospital from January 1995 and July 2007 was analyzed by polymerase chain reaction and restriction fragment length polymorphism assays. The prognostic impact of genotypes of polymorphisms on progression-free survival and overall survival (OS) of EOC patients was examined using the Kaplan–Meier probability estimates and univariate and multivariate Cox proportional hazard ratio (HR) regression analyses. The significant results of Cox analyses were validated using a bootstrap resampling study (1000 replications). At 60 months of follow-up, lower OS was seen in patients with GSTT1 null genotype (50.0 vs. 76.7 %, P = 0.02) compared with the other genotype (Kaplan–Meier estimate). This outcome remained the same in univariate Cox analysis (HR 2.22, P = 0.02). After multivariate Cox analysis, patients with GSTT1 null (HR 2.11, P = 0.04, P bootstrap = 0.04) and NQO2 AA (HR 2.13, P = 0.03, P bootstrap = 0.04) genotypes were under greater risks of progressing to death when compared with those with others genotypes. Our data suggest, for the first time, that inherited abnormalities in xenobiotic detoxification pathway related to GSTT1 and NQO2 c.-102A>C polymorphisms act as independent prognostic factors for OS of EOC patients.
Literature
2.
go back to reference Patch AM, et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature. 2015;521(7553):489–94.CrossRefPubMed Patch AM, et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature. 2015;521(7553):489–94.CrossRefPubMed
3.
go back to reference Pereira D, et al. Improvement of a predictive model in ovarian cancer patients submitted to platinum-based chemotherapy: implications of a GST activity profile. Eur J Clin Pharmacol. 2016;72(5):545–53.CrossRefPubMed Pereira D, et al. Improvement of a predictive model in ovarian cancer patients submitted to platinum-based chemotherapy: implications of a GST activity profile. Eur J Clin Pharmacol. 2016;72(5):545–53.CrossRefPubMed
4.
go back to reference Beeghly A, et al. Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival. Gynecol Oncol. 2006;100(2):330–7.CrossRefPubMed Beeghly A, et al. Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival. Gynecol Oncol. 2006;100(2):330–7.CrossRefPubMed
5.
go back to reference Nagle CM, et al. The role of glutathione-S-transferase polymorphisms in ovarian cancer survival. Eur J Cancer. 2007;43(2):283–90.CrossRefPubMed Nagle CM, et al. The role of glutathione-S-transferase polymorphisms in ovarian cancer survival. Eur J Cancer. 2007;43(2):283–90.CrossRefPubMed
6.
go back to reference Kim HS, et al. Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: a Korean population-based study. Gynecol Oncol. 2009;113(2):264–9.CrossRefPubMed Kim HS, et al. Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: a Korean population-based study. Gynecol Oncol. 2009;113(2):264–9.CrossRefPubMed
7.
go back to reference Khrunin AV, et al. Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients. Pharmacogenom J. 2010;10(1):54–61.CrossRef Khrunin AV, et al. Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients. Pharmacogenom J. 2010;10(1):54–61.CrossRef
9.
go back to reference Chen S, et al. Structure-function studies of DT-diaphorase (NQO1) and NRH: quinone oxidoreductase (NQO2). Free Radic Biol Med. 2000;29(3–4):276–84.CrossRefPubMed Chen S, et al. Structure-function studies of DT-diaphorase (NQO1) and NRH: quinone oxidoreductase (NQO2). Free Radic Biol Med. 2000;29(3–4):276–84.CrossRefPubMed
10.
go back to reference Yu KD, et al. Functional polymorphisms, altered gene expression and genetic association link NRH:quinone oxidoreductase 2 to breast cancer with wild-type p53. Hum Mol Genet. 2009;18(13):2502–17.CrossRefPubMed Yu KD, et al. Functional polymorphisms, altered gene expression and genetic association link NRH:quinone oxidoreductase 2 to breast cancer with wild-type p53. Hum Mol Genet. 2009;18(13):2502–17.CrossRefPubMed
11.
go back to reference Howells RE, et al. Association of glutathione S-transferase GSTM1 and GSTT1 null genotypes with clinical outcome in epithelial ovarian cancer. Clin Cancer Res. 1998;4(10):2439–45.PubMed Howells RE, et al. Association of glutathione S-transferase GSTM1 and GSTT1 null genotypes with clinical outcome in epithelial ovarian cancer. Clin Cancer Res. 1998;4(10):2439–45.PubMed
12.
go back to reference Lallas TA, et al. The glutathione S-transferase M1 genotype in ovarian cancer. Cancer Epidemiol Biomark Prev. 2000;9(6):587–90. Lallas TA, et al. The glutathione S-transferase M1 genotype in ovarian cancer. Cancer Epidemiol Biomark Prev. 2000;9(6):587–90.
13.
go back to reference Morari EC, et al. Role of glutathione-S-transferase and codon 72 of P53 genotypes in epithelial ovarian cancer patients. J Cancer Res Clin Oncol. 2006;132(8):521–8.CrossRefPubMed Morari EC, et al. Role of glutathione-S-transferase and codon 72 of P53 genotypes in epithelial ovarian cancer patients. J Cancer Res Clin Oncol. 2006;132(8):521–8.CrossRefPubMed
14.
go back to reference Kurman RJ, et al. WHO classification of tumours of female reproductive organs. 4th ed. Lyon: IARC Press; 2014. Kurman RJ, et al. WHO classification of tumours of female reproductive organs. 4th ed. Lyon: IARC Press; 2014.
15.
go back to reference Prat J. FIGO, Committee on Gynecologic Oncology. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2014;124(1):1–5.CrossRefPubMed Prat J. FIGO, Committee on Gynecologic Oncology. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2014;124(1):1–5.CrossRefPubMed
16.
go back to reference Prahm KP, et al. The prognostic value of dividing epithelial ovarian cancer into type I and type II tumors based on pathologic characteristics. Gynecol Oncol. 2015;136(2):205–11.CrossRefPubMed Prahm KP, et al. The prognostic value of dividing epithelial ovarian cancer into type I and type II tumors based on pathologic characteristics. Gynecol Oncol. 2015;136(2):205–11.CrossRefPubMed
17.
go back to reference Arruda VR, et al. Increased risk for acute myeloid leukaemia in individuals with glutathione S-transferase mu 1 (GSTM1) and theta 1 (GSTT1) gene defects. Eur J Haematol. 2001;66(6):383–8.CrossRefPubMed Arruda VR, et al. Increased risk for acute myeloid leukaemia in individuals with glutathione S-transferase mu 1 (GSTM1) and theta 1 (GSTT1) gene defects. Eur J Haematol. 2001;66(6):383–8.CrossRefPubMed
18.
go back to reference Hohaus S, et al. Glutathione S-transferase P1 genotype and prognosis in Hodgkin’s lymphoma. Clin Cancer Res. 2005;11(6):2175–9.CrossRefPubMed Hohaus S, et al. Glutathione S-transferase P1 genotype and prognosis in Hodgkin’s lymphoma. Clin Cancer Res. 2005;11(6):2175–9.CrossRefPubMed
20.
go back to reference Fagerholm R, et al. NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. Nat Genet. 2008;40(7):844–53.CrossRefPubMed Fagerholm R, et al. NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. Nat Genet. 2008;40(7):844–53.CrossRefPubMed
Metadata
Title
Association between polymorphisms in xenobiotic detoxification-related genes with prognosis of epithelial ovarian cancer
Authors
Juliana Carron
Angelo Borsarelli Carvalho Brito
Ana Carolina Mourão Torelli
Cristiane Oliveira
Sophie Françoise Mauricette Derchain
Carmen Silvia Passos Lima
Gustavo Jacob Lourenço
Publication date
01-10-2016
Publisher
Springer US
Published in
Medical Oncology / Issue 10/2016
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-016-0819-8

Other articles of this Issue 10/2016

Medical Oncology 10/2016 Go to the issue